CAR-T therapy study for advanced blood and solid cancers
Part of Cancer clinical trials.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced blood cancer (like multiple myeloma or lymphoma) or solid tumor (like small cell lung cancer) that has come back or not responded to treatment.
- Your cancer cells have a specific target protein (like BCMA, GPRC5D, or DLL3) that the therapy is designed to attack.
- You are generally able to care for yourself (ECOG score 0-2 for blood cancers or 0-1 for solid tumors) and expected to live at least 3 more months.
- Your major organs (like heart, kidneys, liver) are working well enough.
- If you can become pregnant, you agree to use effective birth control during the study and for 1 year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment that targets both CD19 and BCMA proteins on cancer cells. It may help people with multiple myeloma, plasma cell leukemia, or related cancers that have not responded to at least three prior treatments.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial tests a new CAR T-cell therapy made from your own immune cells to treat advanced cancers that have not responded to other treatments. It may be an option if your tumor has a specific target and you are otherwise healthy enough.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Hear when a new Advanced Malignant Tumours trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.